This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Does Tetra (TTEK) Have the Potential to Rally 26.27% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Tetra (TTEK) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TTEKNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think EverQuote (EVER) Could Surge 26.01%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 26% upside potential for EverQuote (EVER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
EVERNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does McGraw Hill, Inc. (MH) Have the Potential to Rally 25.42% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in McGraw Hill, Inc. (MH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MHNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe AvePoint (AVPT) Could Rally 49.25%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 49.3% upside potential for AvePoint (AVPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AVPTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 37.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TNGXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think On Holding (ONON) Could Surge 26.11%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for On Holding (ONON) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ONONPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Orla Mining (ORLA) Could Surge 33.33%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 33.3% upside potential for Orla Mining (ORLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ORLAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Five9 (FIVN) Could Surge 64.41%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Five9 (FIVN) points to a 64.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
FIVNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 32.8% upside potential for Caris Life Sciences,?Inc. (CAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CAINegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Certara (CERT) Could Surge 43.28%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.3% in Certara (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CERTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Prestige Consumer Healthcare (PBH) Could Rally 26.06%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 26.1% upside potential for Prestige Consumer Healthcare (PBH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PBHPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Hallador Energy (HNRG) Have the Potential to Rally 33.68% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 33.7% upside potential for Hallador Energy (HNRG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
HNRGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Pony AI Inc. - Sponsored ADR (PONY) Could Rally 70.63%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Pony AI Inc. - Sponsored ADR (PONY) points to a 70.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PONYNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 106% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OCSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BNTCPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PROFNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TBPHPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Atlassian (TEAM) Could Surge 50.43%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Atlassian (TEAM) points to a 50.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TEAMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MLYSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 63.99% Upside in Pagaya Technologies Ltd. (PGY): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 64% in Pagaya Technologies Ltd. (PGY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PGYNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Sprinklr (CXM)? Wall Street Analysts Think 32.91%
by Zacks Equity Research
The mean of analysts' price targets for Sprinklr (CXM) points to a 32.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CXMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 29.72% Upside in Archer Aviation (ACHR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Archer Aviation (ACHR) points to a 29.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ACHRNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Costco (COST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Costco (COST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COSTPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Earnings Preview: Lululemon (LULU) Q3 Earnings Expected to Decline
by Zacks Equity Research
Lululemon (LULU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LULUNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Broadcom Inc. (AVGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Broadcom Inc. (AVGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVGOPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate